| Literature DB >> 35677531 |
Kee Tat Lee1, Nurul Akmar Misron2, Norasmidar Abdul Aziz1, Chin Hau Wong1, Hong Keng Liew1.
Abstract
Plasmablastic lymphoma (PBL) is a rare and highly aggressive type of lymphoma, which is commonly associated with human immunodeficiency virus (HIV) infection. Spontaneous regression of aggressive lymphomas is rare as they typically require administration of chemotherapy and radiotherapy for treatment. Here, we describe a case of a spontaneous regression of PBL after nasal biopsy and computed tomography (CT) guided biopsy of paravertebral mass in an immunocompetent patient. We postulate that the patient's immune system may be activated as a result of the stress and physical trauma brought on by nasal and paravertebral mass biopsy. Our case highlights the rare phenomenon of spontaneous regression of lymphoma which needs to be further studied on to establish its underlying pathophysiology.Entities:
Year: 2022 PMID: 35677531 PMCID: PMC9170507 DOI: 10.1155/2022/1142049
Source DB: PubMed Journal: Case Rep Hematol ISSN: 2090-6579
Figure 1CT showing a well-defined heterogeneously enhancing mass at the left paravertebral region with extension into left T7/8 neural foramina. (a)-(b) Axial view; (c) coronal view.
Figure 2Nasopharyngeal mass biopsy. Hematoxylin and eosin staining ((a) original magnification ×40) and immunohistochemical staining were positive for MUM-1 ((b) original magnification ×40), CD79a ((c) original magnification ×40), kappa ((d) original magnification ×40), and lambda ((e) original magnification ×40) and negative for CD20 ((f) original magnification ×40).
Figure 3Initial CT showing a mass over left frontal and ethmoid sinuses which occupied almost the entire left nasal cavity (a). Repeated CT showing regression of left nasal mass (b).
Summary of clinical characteristic of spontaneous regression of PBL cases without antineoplastic therapy.
| No. | Age/sex | Immune status | B symptom | Stagea | Primary site | Nodal | Therapy | Follow up | Recurrence |
|---|---|---|---|---|---|---|---|---|---|
| 1 [ | 35/male | Yes/HIV | No | I | Maxilla | No | HAART | 1 month | No |
| 2 [ | 55/female | Yes/HIV | N/A | N/A | Oral cavity | N/A | HAART | 10 months | No |
| 3 [ | 78/female | Yes/MTX treatment | N/A | II | Buccal mucosa | Yes (cervical) | Decrease dose of MTX | 2 years | No |
| 4 [ | 80/male | No | No | I | Maxilla | No | No | 5 months | No |
| 5 [ | 80/male | No | No | I | Gingiva | No | No | N/A | No |
| 6 [ | 66/female | Yes/HIV | No | I | Maxilla | No | HAART | 12 months | No |
| 7 [ | 69/male | Yes/MTXb treatment | No | IV | N/Ac | No | Stop MTX | 12 weeks | No |
| 8 [ | 69/male | No | No | I | Gingiva | N/A | No | 2 years | No |
| 9 | 61/male | No | No | I | Nasal | No | No | 4 years | No |
aAssessed using Ann Arbor staging. bMTX, methotrexate. cN/A, not available.